US Physicians Strongly Support COVID-19 Boosters, But Stop Short of Widespread Booster Recommendations, Says New InCrowd Data


October 15, 2021

As key FDA committee meets this week, 86% of doctors agree on Pfizer-BioNTech COVID-19 booster shot importance for key groups, but estimate 18% of wishful patients will be ineligible 


WATERTOWN, MA October 15, 2021—As the FDA’s Vaccines and Related Biological Products Advisory Committee meets this week to discuss COVID-19 boosters for Moderna and Johnson & Johnson (J&J) vaccines, new data show 86% of US physicians agree on the importance of the Pfizer-BioNTech COVID-19 booster for patients aged 65 and older, and those with preexisting conditions. Seventy eight percent agreed that Pfizer-BioNTech boosters should be administered to those adults with increased exposure due to occupational or institutional settings. Furthermore, physicians estimate that 54% of their patients have already obtained a Pfizer booster (17%) or intend to do so (37%).

Post a Comment

You must be logged in to post a Comment.